Valneva’s Brazil Vaccine Green Light Comes With a Stock-Market Catch
SÃO PAULO, May 12, 2026, 14:07 Valneva’s Brazilian partner has secured approval to produce the chikungunya vaccine locally, paving a route for the shot to potentially enter Brazil’s public health system. The update lands as Valneva’s stock faces a turbulent stretch. Anvisa, the national health regulator, authorized Instituto Butantan to handle manufacturing in Brazil. Until now, only Valneva’s own factories had been listed as production sites since the vaccine’s 2025 approval.